LT2651965T - Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis - Google Patents

Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis

Info

Publication number: LT2651965T
Authority: LT; Lithuania
Prior art keywords: amino acid; molecules modified; analogue molecules; cyclosporine analogue; cyclosporine
Prior art date: 2010-12-15

Application number

LTEP11848865.9T

Other languages

English (en)

Inventor

Alexander Hegmans

Bruce Fenske

Dan Trepanier

Mark Abel

Shin Sugiyama

Daren R. Ure

Original Assignee

Contravir Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-15

Filing date

2011-12-14

Publication date

2019-01-10

2011-12-14 Application filed by Contravir Pharmaceuticals, Inc. filed Critical Contravir Pharmaceuticals, Inc.

2019-01-10 Publication of LT2651965T publication Critical patent/LT2651965T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Virology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)

LTEP11848865.9T 2010-12-15 2011-12-14 Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis LT2651965T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42357610P	2010-12-15	2010-12-15
PCT/CA2011/050773 WO2012079172A1 (en)	2010-12-15	2011-12-14	Cyclosporine analogue molecules modified at amino acid 1 and 3

Publications (1)

Publication Number	Publication Date
LT2651965T true LT2651965T (lt)	2019-01-10

Family

ID=46243924

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11848865.9T LT2651965T (lt)	2010-12-15	2011-12-14	Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis

Country Status (25)

Country	Link
US (2)	US9200038B2 (lt)
EP (2)	EP2651965B1 (lt)
JP (3)	JP6144627B2 (lt)
KR (3)	KR102011339B1 (lt)
CN (2)	CN107496902B (lt)
AU (1)	AU2011342284C1 (lt)
BR (1)	BR112013014890B1 (lt)
CA (1)	CA2821009C (lt)
DK (1)	DK2651965T3 (lt)
ES (1)	ES2705750T3 (lt)
HR (1)	HRP20190096T1 (lt)
HU (1)	HUE042490T2 (lt)
IL (1)	IL226792A (lt)
LT (1)	LT2651965T (lt)
MX (1)	MX353720B (lt)
MY (2)	MY192981A (lt)
NZ (1)	NZ611620A (lt)
PH (1)	PH12013501213A1 (lt)
PL (1)	PL2651965T3 (lt)
PT (1)	PT2651965T (lt)
RU (1)	RU2630690C9 (lt)
SG (2)	SG191069A1 (lt)
SI (1)	SI2651965T1 (lt)
TR (1)	TR201900128T4 (lt)
WO (1)	WO2012079172A1 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
JP6144627B2 (ja) *	2010-12-15	2017-06-07	コントラヴィアファーマシューティカルズ、インク．	アミノ酸１および３で修飾されたシクロスポリン類似体分子
EP2855508B1 (en)	2012-06-01	2018-02-14	Allergan, Inc.	Cyclosporin a analogs
WO2014132084A1 (en) *	2013-03-01	2014-09-04	Ucl Business Plc	Non-immunosuppressive cyclosporin derivatives as antiviral agents
SG11201601274QA (en) *	2013-08-26	2016-03-30	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c
WO2016112321A1 (en)	2015-01-08	2016-07-14	Allergan, Inc.	Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
CN118324867A (zh) *	2016-05-17	2024-07-12	美国科技环球有限公司	新型环孢菌素衍生物及其用途
EP3551034A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en)	2016-12-08	2018-06-14	Contravir Pharmaceuticals, Inc.	Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
WO2018112255A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an immunosuppressant
AR111464A1 (es)	2017-04-14	2019-07-17	Contravir Pharmaceuticals Inc	Terapia combinada para el tratamiento de infecciones virales
EP3612540A1 (en)	2017-04-20	2020-02-26	Rising Tide Foundation	Triphenylphosphonium-tethered tetracycyclines for use in treating cancer
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
ES2990218T3 (es) *	2018-08-22	2024-11-29	Bacainn Biotherapeutics Ltd	Composiciones de ciclosporina y métodos de uso
US12594275B2 (en)	2019-02-07	2026-04-07	The Regents Of The University Of California	Immunophilin binding agents and uses thereof
CN115427060A (zh)	2020-02-19	2022-12-02	海必恩制药公司	环孢菌素类似物用于治疗纤维化的用途
AU2021227230A1 (en) *	2020-02-25	2022-09-08	Hepion Pharmaceuticals, Inc.	Use of cyclosporine analogues for treating cancer
TW202144378A (zh) *	2020-03-26	2021-12-01	大陸商睿諾醫療科技（上海）有限公司	親環蛋白抑制劑及其用途
IL296586B1 (en)	2020-03-26	2026-04-01	Farsight Medical Tech Shanghai Co Ltd	Cyclophilin inhibitors and their uses
AU2021388171A1 (en) *	2020-11-29	2023-06-22	Hepion Pharmaceuticals, Inc.	Use of cyclosporine analogues as antithrombotic agents
CN113173974B (zh) *	2021-03-18	2024-09-06	北京大学深圳研究生院	环孢素衍生物的合成方法
CN115677533B (zh) *	2021-07-30	2023-12-05	沈阳化工研究院有限公司	一种4-庚基苯甲腈的制备方法
IT202300001116A1 (it) *	2023-01-25	2024-07-25	Indena Spa	Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
CN121219307A (zh) *	2023-06-02	2025-12-26	睿诺医疗科技（上海）有限公司	亲环蛋白抑制剂及其用途
EP4724081A2 (en) *	2023-06-08	2026-04-15	Hepion Pharmaceuticals, Inc.	Solid state forms of rencofilstat

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (lt)	1975-11-04	1979-12-28	Sandoz Ag
US4210581A (en)	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4160452A (en)	1977-04-07	1979-07-10	Alza Corporation	Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
DE2819094A1 (de)	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv)	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
EP0034567B1 (en)	1980-02-14	1984-11-07	Sandoz Ag	A method for the total synthesis of cyclosporins and novel cyclosporins
US4396542A (en)	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DE3260468D1 (en)	1981-01-09	1984-09-06	Sandoz Ag	Novel cyclosporins
CH667274A5 (de)	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPS6182786A (ja)	1984-09-28	1986-04-26	ブラザー工業株式会社	ミシン
EP0194972B1 (en)	1985-03-11	1992-07-29	Sandoz Ag	Novel cyclosporins
US4764503A (en)	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
US4885276A (en)	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en)	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
ES2059558T3 (es)	1987-06-17	1994-11-16	Sandoz Ag	Ciclosporins y su uso como productos farmaceuticos.
ATE110784T1 (de)	1987-06-19	1994-09-15	Sandoz Ag	Zyklische peptolide.
DE3888357T2 (de)	1987-06-22	1994-09-15	Merck & Co Inc	Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
GB8717300D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
US5227467A (en)	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US5236899A (en)	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en)	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
JPH04502328A (ja)	1988-12-05	1992-04-23	ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク	シクロスポリンａの新規誘導体、それに対する抗体及びその使用
US5604092A (en)	1988-12-05	1997-02-18	The Trustees Of Columbia University In The City Of New York	Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein
US5284826A (en)	1989-07-24	1994-02-08	Sandoz Ltd.	0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en)	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en)	1990-02-27	1993-05-25	Merck & Co., Inc.	Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
ATE148469T1 (de)	1990-11-02	1997-02-15	Sandoz Ag	Zyklosporine
GB9204466D0 (en)	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
WO1997011092A1 (en)	1994-04-07	1997-03-27	Nippon Shinyaku Co., Ltd.	Cyclosporin phosphate derivatives and medicinal composition
US5639852A (en)	1994-09-01	1997-06-17	Wisconsin Alumni Research Foundation	Immunostimulatory agents
US5948693A (en)	1994-09-01	1999-09-07	Wisconsin Alumni Research Foundation	Solid phase synthesis of immunosuppressive agents
JPH08148407A (ja)	1994-11-21	1996-06-07	Nikon Corp	照明光学装置
SE520730C2 (sv)	1995-01-20	2003-08-19	Eskil Elmer	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
KR100241643B1 (ko)	1995-06-06	2000-03-02	디. 제이. 우드	당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
PL324531A1 (en)	1995-07-17	1998-06-08	Chem Ag C	Derivatives of cyclosporin effective against hiv virus
JP3089350B2 (ja)	1995-11-20	2000-09-18	ギルフォードファーマシューティカルズインコーポレイテッド	シクロフィリンロタマーゼ活性の阻害剤
FR2757520B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr)	1997-04-30	1999-12-10	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1999010374A1 (en)	1997-08-26	1999-03-04	Wisconsin Alumni Research Foundation	Cyclosporin a conjugates and uses therefor
US6270957B1 (en)	1997-08-26	2001-08-07	Wisconsin Alumni Research Foundation	Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
AU750245B2 (en)	1997-10-08	2002-07-11	Aurinia Phamaceuticals Inc.	Deuterated cyclosporine analogs and their use as immunomodulating agents
US5990274A (en)	1997-11-25	1999-11-23	Dade Behring Inc.	Cyclosporine derivatives and uses thereof
FR2772768B1 (fr)	1997-12-19	2000-01-14	Rhone Poulenc Rorer Sa	Nouveau procede de preparation de derives de cyclosporine
ES2212583T3 (es)	1998-06-12	2004-07-16	C-Chem Ag	Nuevas ciclosporinas.
FR2780061B1 (fr)	1998-06-22	2001-09-07	Rhone Poulenc Rorer Sa	Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt)	1998-07-01	2006-05-31	Debiopharm Sa	Nova ciclosporina com um perfil de actividade melhorado
ES2267492T3 (es)	1999-02-05	2007-03-16	Debiopharm S.A.	Derivados de ciclosporina y procedimiento de preparacion de dichos derivados.
US6521595B1 (en)	1999-11-19	2003-02-18	Lg Chemical, Ltd.	Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
CN1391458A (zh)	1999-11-19	2003-01-15	Lg生活健康株式会社	非免疫抑制性环孢菌素衍生物在促进毛发生长中的应用
KR20020039528A (ko)	2000-11-22	2002-05-27	조명재	사이클로스포린 7- 티오아미드 유도체를 유효성분으로하는 모발성장촉진제
KR100360716B1 (ko)	2000-11-22	2002-11-13	주식회사 엘지생활건강	사이클로스포린 에이 7- 티오아미드 유도체를유효성분으로 하는 모발성장촉진제
KR100681670B1 (ko)	2001-02-14	2007-02-09	주식회사 엘지생활건강	[감마 히드록시 엔- 메틸-엘-루신9]사이클로스포린 에이를유효성분으로 하는 모발 성장 촉진제
US6784156B2 (en)	2001-03-05	2004-08-31	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of respiratory diseases
DE60208180T2 (de)	2001-04-20	2006-08-17	Debiopharm S.A.	Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
KR100465012B1 (ko)	2001-05-11	2005-01-13	주식회사 엘지생활건강	모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
KR100695611B1 (ko)	2001-05-17	2007-03-14	주식회사 엘지생활건강	[감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제
US6809077B2 (en)	2001-10-12	2004-10-26	Enanta Pharmaceuticals, Inc.	Cyclosporin analogs for the treatment of autoimmune diseases
US20030087813A1 (en)	2001-10-12	2003-05-08	Or Yat Sun	Cyclosporin analogs for the treatment of lung diseases
EP2116228A1 (en)	2001-10-19	2009-11-11	Isotechnika Inc.	Novel cyclosporin analog microemulsion preconcentrates
ES2310604T3 (es)	2001-10-19	2009-01-16	Isotechnika, Inc.	Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
WO2003033526A2 (en)	2001-10-19	2003-04-24	Isotechnika Inc.	Synthesis of cyclosporin analogs
US6987090B2 (en)	2002-05-09	2006-01-17	Lg Household & Health Care Ltd.	Use of 3-position cyclosporin derivatives for hair growth
KR100641295B1 (ko) *	2002-11-11	2006-10-31	김성수	사이클로필린의 항산화제로서의 용도 및 사이클로필린의과발현에 의해 세포이식에서 사이클로스포린 ａ에 의해유발되는 세포독성의 방지
US20040110666A1 (en)	2002-12-04	2004-06-10	Or Yat Sun	Cyclosporins for the treatment of immune disorders
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
JP2006524232A (ja)	2003-03-17	2006-10-26	アルバニーモレキュラーリサーチインコーポレーティッド	新規サイクロスポリン
ITMI20030627A1 (it)	2003-03-31	2004-10-01	Polimeri Europa Spa	Polimeri vinilaromatici espandibili e procedimento per la loro preparazione.
TW200505946A (en)	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
WO2004089940A1 (en) *	2003-04-11	2004-10-21	Glenmark Pharmaceuticals S.A.	Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US20040266669A1 (en)	2003-06-20	2004-12-30	Wu Frank X. H.	Cyclosporin derivatives for the treatment of immune disorders
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
DE102004011988A1 (de)	2004-03-11	2005-09-22	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Cyclosporinderivate und diese enthaltende pharmazeutische Zusammensetzungen
US20060015374A1 (en)	2004-07-19	2006-01-19	Yanhong Ochs	Risk management on the application of crop inputs
US7799756B2 (en)	2004-07-29	2010-09-21	Albany Molecular Research, Inc.	Processes for stereoselective synthesis of trans ISATX247
US7226906B2 (en)	2004-08-16	2007-06-05	Array Biopharma, Inc.	Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
US20060035821A1 (en)	2004-08-16	2006-02-16	Hunt Kevin W	Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
EP1804823A4 (en) *	2004-09-29	2010-06-09	Amr Technology Inc	NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
JP2008514701A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
JP5139065B2 (ja)	2004-10-01	2013-02-06	スシネキスインク	Ｃ型肝炎感染の治療及び予防のための３−エーテル及び３−チオエーテル置換シクロスポリン誘導体
US7361636B2 (en)	2004-10-06	2008-04-22	Amr Technology, Inc.	Cyclosporin alkynes and their utility as pharmaceutical agents
US7696167B2 (en)	2004-11-22	2010-04-13	Astellas Pharma Inc.	Cyclic peptide compound
CA2592343A1 (en)	2004-12-17	2006-06-22	Isotechnika Inc.	Metabolites of cyclosporin analogs
US8329658B2 (en)	2005-09-30	2012-12-11	Scynexis, Inc.	Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US7696165B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US20070232532A1 (en)	2006-03-28	2007-10-04	Amr Technology, Inc.	Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7576057B2 (en)	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
AU2009268549B2 (en) *	2008-07-10	2015-07-16	Allergan, Inc.	Cyclosporin derivatives for treating ocular and dermal diseases and conditions
BRPI0911709A2 (pt)	2008-07-30	2017-06-20	Isotechnika Labs Inc	composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
SG173180A1 (en)	2009-01-30	2011-09-29	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c infection
WO2010138422A1 (en) *	2009-05-27	2010-12-02	Allergan, Inc.	Cyclosporin derivatives for enhancing the growth of hair
AU2010339460A1 (en) *	2009-12-30	2012-07-19	Scynexis Inc.	Cyclosporine analogues
US9175042B2 (en) *	2010-10-12	2015-11-03	Allergan, Inc.	Cyclosporin analogs
RU2013119869A (ru) *	2010-10-12	2014-11-20	Аллерган, Инк.	Аналоги циклоспорина
JP6144627B2 (ja) *	2010-12-15	2017-06-07	コントラヴィアファーマシューティカルズ、インク．	アミノ酸１および３で修飾されたシクロスポリン類似体分子

2011
- 2011-12-14 JP JP2013543478A patent/JP6144627B2/ja active Active
- 2011-12-14 WO PCT/CA2011/050773 patent/WO2012079172A1/en not_active Ceased
- 2011-12-14 PT PT11848865T patent/PT2651965T/pt unknown
- 2011-12-14 MY MYPI2018000135A patent/MY192981A/en unknown
- 2011-12-14 TR TR2019/00128T patent/TR201900128T4/tr unknown
- 2011-12-14 LT LTEP11848865.9T patent/LT2651965T/lt unknown
- 2011-12-14 EP EP11848865.9A patent/EP2651965B1/en active Active
- 2011-12-14 KR KR1020137016342A patent/KR102011339B1/ko active Active
- 2011-12-14 SI SI201131640T patent/SI2651965T1/sl unknown
- 2011-12-14 MX MX2013006831A patent/MX353720B/es active IP Right Grant
- 2011-12-14 KR KR1020187037529A patent/KR20190002731A/ko not_active Ceased
- 2011-12-14 KR KR1020207007384A patent/KR102305423B1/ko active Active
- 2011-12-14 US US13/994,707 patent/US9200038B2/en active Active
- 2011-12-14 RU RU2013127162A patent/RU2630690C9/ru active
- 2011-12-14 CN CN201710804889.2A patent/CN107496902B/zh active Active
- 2011-12-14 BR BR112013014890-0A patent/BR112013014890B1/pt active IP Right Grant
- 2011-12-14 PH PH1/2013/501213A patent/PH12013501213A1/en unknown
- 2011-12-14 MY MYPI2013002159A patent/MY165152A/en unknown
- 2011-12-14 AU AU2011342284A patent/AU2011342284C1/en active Active
- 2011-12-14 HU HUE11848865A patent/HUE042490T2/hu unknown
- 2011-12-14 SG SG2013044276A patent/SG191069A1/en unknown
- 2011-12-14 SG SG10201510236XA patent/SG10201510236XA/en unknown
- 2011-12-14 DK DK11848865.9T patent/DK2651965T3/en active
- 2011-12-14 HR HRP20190096TT patent/HRP20190096T1/hr unknown
- 2011-12-14 CA CA2821009A patent/CA2821009C/en active Active
- 2011-12-14 ES ES11848865T patent/ES2705750T3/es active Active
- 2011-12-14 NZ NZ611620A patent/NZ611620A/en unknown
- 2011-12-14 CN CN201180067449.4A patent/CN103443119B/zh active Active
- 2011-12-14 EP EP18187927.1A patent/EP3461835A1/en active Pending
- 2011-12-14 PL PL11848865T patent/PL2651965T3/pl unknown
2013
- 2013-06-06 IL IL226792A patent/IL226792A/en active IP Right Grant
2015
- 2015-10-30 US US14/928,885 patent/US9714271B2/en active Active
2017
- 2017-02-13 JP JP2017024484A patent/JP6831259B2/ja active Active
2019
- 2019-02-04 JP JP2019018182A patent/JP2019123712A/ja active Pending

Also Published As

Publication number	Publication date
IL226792A (en)	2017-10-31
AU2011342284A1 (en)	2013-07-18
CN103443119A (zh)	2013-12-11
NZ611620A (en)	2016-02-26
MY165152A (en)	2018-02-28
TR201900128T4 (tr)	2019-02-21
CA2821009A1 (en)	2012-06-21
US9200038B2 (en)	2015-12-01
JP6144627B2 (ja)	2017-06-07
MY192981A (en)	2022-09-20
SG191069A1 (en)	2013-07-31
RU2630690C2 (ru)	2017-09-12
BR112013014890B1 (pt)	2023-10-24
US20160207961A1 (en)	2016-07-21
HUE042490T2 (hu)	2019-07-29
SI2651965T1 (sl)	2019-03-29
HK1243633A1 (zh)	2018-07-20
CA2821009C (en)	2019-03-05
HRP20190096T1 (hr)	2019-02-22
RU2630690C9 (ru)	2017-12-28
KR102305423B1 (ko)	2021-09-27
CN107496902A (zh)	2017-12-22
KR20200029639A (ko)	2020-03-18
CN103443119B (zh)	2017-09-22
MX353720B (es)	2018-01-25
PL2651965T3 (pl)	2019-04-30
AU2011342284C1 (en)	2017-07-13
JP2019123712A (ja)	2019-07-25
MX2013006831A (es)	2014-10-14
EP3461835A1 (en)	2019-04-03
JP2017128577A (ja)	2017-07-27
EP2651965A4 (en)	2017-08-09
KR20190002731A (ko)	2019-01-08
BR112013014890A2 (pt)	2020-08-04
US9714271B2 (en)	2017-07-25
DK2651965T3 (en)	2019-02-18
JP2014505035A (ja)	2014-02-27
ES2705750T3 (es)	2019-03-26
JP6831259B2 (ja)	2021-02-17
KR20130124515A (ko)	2013-11-14
SG10201510236XA (en)	2016-01-28
EP2651965A1 (en)	2013-10-23
WO2012079172A1 (en)	2012-06-21
PH12013501213A1 (en)	2016-12-16
PT2651965T (pt)	2019-01-28
EP2651965B1 (en)	2018-12-12
AU2011342284B2 (en)	2017-02-16
RU2013127162A (ru)	2015-06-10
US20140142033A1 (en)	2014-05-22
KR102011339B1 (ko)	2019-08-16
CN107496902B (zh)	2022-01-18

Publication	Publication Date	Title
SG10201510236XA (en)	2016-01-28	Cyclosporine analogue molecules modified at amino acid 1 and 3
ZA201207331B (en)	2014-07-30	Concentrated protein formulations and uses thereof
IL229353B (en)	2019-03-31	Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
IL222961A0 (en)	2013-02-03	Novel dna-dinding proteins and uses thereof
SI2391620T1 (sl)	2014-08-29	Z alkilaminom substituiran dicianopiridin in njegova predzdravila estra amino kisline
IL248880A0 (en)	2017-01-31	Preparations containing r-g-cysteic acid peptides and their uses
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
EP2408802A4 (en)	2013-04-17	CYCLIC AMINO ACID MOLECULES AND THEIR METHODS OF SYNTHESIS
GB201010557D0 (en)	2010-08-11	RNA molecules and uses thereof
PL2588491T3 (pl)	2017-03-31	Nowy peptyd i jego zastosowanie
ZA201003681B (en)	2015-12-23	Compositions and methods comprising basic amino acid peptides and proteases
IL188681A0 (en)	2008-12-29	Pharmaceutical compositions and methods utilizing a d-amino acid
ZA201106665B (en)	2013-02-27	Products comprising n-phenylpropenoyl amino acid amides and uses thereof
EP2593595A4 (en)	2014-03-26	NOVEL PEPTIDES AND USES THEREOF
IL210704A0 (en)	2011-03-31	Nonimmunosuppresive cyclosporine analogue molecules
IL232867A0 (en)	2014-07-31	Preparations of bacteriophage gene 3 protein and use as amyloid binding agents
PL2627668T3 (pl)	2017-08-31	Peptydy i ich zastosowanie
PL2464656T3 (pl)	2015-12-31	Nowy peptyd i jego zastosowanie
IL209595A0 (en)	2011-01-31	Variant hhip1 protein and methods and uses thereof
ZA201305485B (en)	2015-01-28	Plant protein hydrolysates
SG173752A1 (en)	2011-09-29	Modifications of cupredoxin derived peptides and methods of use thereof
EP2668958A4 (en)	2014-10-08	CASPOFUNGIN ANALOGS AND APPLICATIONS THEREOF
TWI369211B (en)	2012-08-01	An isolated peptide and the preparation processes and applications thereof
IL219182A0 (en)	2012-06-28	2-amino-3-methyl-hex-5-enoic acid and its use in the production of peptides such as bacitracins
PL392256A1 (pl)	2011-10-10	N-(Bisfosfonometylo)lizyny oraz sposób ich wytwarzania